Erfahrungen mit neuartigen N-Lost-Phosphamidestern

Drings, P.; Allner, R.; Brock, Nelson L.; Burkert, H.; Fischer, Marc; Fölsch, E.; Gerhartz, H; Götzky, P.; Hoppe, I.; Kanzler, G.; Klein, H.; Mainzer, K.; Martin, H.; Obrecht, P.; Palme, G.; Paulisch, H.; Riegg, H.; Schubert, Jörg; Treske, U.; Weise, Wolfgang; Willems, Deborah L.; Wilmanns, H.; Witte, Steffen; Wohlenberg, Holger

doi:10.1055/s-0028-1108490

Cited by 19 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Primary treatment of elderly, frail patients often poses a similar dilemma. The oxazaphosphorine trofosfamide (1) has been used in the treatment of various solid tumours and malignant lymphomas (2)(3)(4). The tolerance for the drug is good, especially in older patients (4).…”

mentioning

confidence: 99%

Trofosfamide in Non-Hodgkin's Lymphoma a Phase II Study

Wist

Risberg

1991

Acta Oncologica

View full text Add to dashboard Cite

mentioning

confidence: 99%

Trofosfamide in Non-Hodgkin's Lymphoma a Phase II Study

Wist

Risberg

1991

Acta Oncologica

View full text Add to dashboard Cite

“…Furthermore, most of the patients were heavily pretreated. Trofosfamide showed surprisingly high response rates (CR + PR) in ovarian cancer [24], cancer of unknown primary (CUP) [12], small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) [8,[30][31][32][33]. Very interesting data were reported by Wolff and coworkers [30][31][32].…”

Section: Trofosfamide In the Treatment Of Other Solid Carcinomasmentioning

confidence: 52%

“…One of the first reports on the effectiveness of trofosfamide in the treatment of malignant lymphomas was published by Drings and coworkers [8]. In a retrospective analysis of 156 patients with various malignant lymphomas (including 49 patients with Hodgkin's disease) 94 patients (approx.…”

Section: Trofosfamide In the Treatment Of Malignant Lymphomasmentioning

confidence: 99%

Trofosfamide in the Palliative Treatment of Cancer: A Review of the Literature

Latz

Nassar²,

Frank³

2004

Oncol Res Treat

View full text Add to dashboard Cite

Trofosfamide is an alkylating agent that is derived from the oxazaphoshorines. It has found application in a broad spectrum of malignancies in the last three decades. The main indications for application were in the palliative situation and as maintenance therapy. Good results were reported from the treatment of non-Hodgkin’s lymphomas and soft tissue sarcomas. A lot of small studies and casuistic contributions are available giving treatment results of several solid carcinomas (malignant gliomas, ovarian, lung and prostate cancer, and others). Due to its oral formulation and good tolerability trofosfamide is an attractive candidate for the palliative situation because treatment on an outpatient basis is possible. However, there is still a lack of randomized clinical studies with trofosfamide. Thus, evidence-based conclusions on the therapeutic value of the drug cannot be drawn. In the future, phase III trials should be untertaken.

show abstract

“…Trofosfamide was chosen because of its known antilymphoma activity [1,11,17,23,31] and the assumed cytostatic effect in intraocular fluids, based on the good CSF penetration of the main metabolite ifosfamide [32]. Moreover, its favorable side effect profile and its potential for treatment monitoring on an outpatient basis were taken into consideration.…”

Section: Discussionmentioning

confidence: 99%

“…Trofosfamide is an alkylating cytostatic agent most commonly used for maintenance therapy of hematologic malignancies [1,11,17,23,31]. The bioavailability of DOI 10.1007/s00417-004-0947-2 trofosfamide is nearly 100% [29].…”

Section: Introductionmentioning

confidence: 99%